Teva signs global multiple sclerosis biosimilar agreement

• Teva executed a global licensing agreement with Polpharma Biologics for a proposed multiple sclerosis biosimilar.
• The company expects to handle commercialization and regulatory submissions across key global markets.
• Management stated the partnership supports its broader corporate strategy to expand biologic medicine access.

Teva (NYSE:TEVA) signed a global licensing agreement with Polpharma Biologics for a proposed multiple sclerosis biosimilar.

The transaction covers both the intravenous and subcutaneous application forms of the ocrelizumab medication.

Polpharma Biologics will handle the primary development and physical manufacturing processes for the proposed medicine.

The company stated it will manage all commercialization and regulatory submissions across key global markets.

Management stated the deal supports corporate expansion.

The business stated this partnership directly aligns with its ongoing Pivot to Growth corporate strategy.

This strategic framework aims to increase broader market access to various biologic medicines globally.